Premium
Acute myeloid leukaemia ( AML ) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3 ‐ITD status: a report from the Children's Oncology Group
Author(s) -
Tarlock Katherine,
Alonzo Todd A.,
Moraleda Pilar P.,
Gerbing Robert B.,
Raimondi Susana C.,
Hirsch Betsy A.,
Ravindranath Yaddanapudi,
Lange Beverly,
Woods William G.,
Gamis Alan S.,
Meshinchi Soheil
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12852
Subject(s) - medicine , myeloid leukaemia , overall survival , oncology , myeloid , complete remission , gastroenterology , chemotherapy
Summary Acute myeloid leukaemia ( AML ) with t(6;9)(p23;q34) is a rare subtype associated with FLT3 ‐internal tandem duplication ( ITD ) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3 ‐ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without FLT3 ‐ITD had an OS of 40% and 27% respectively ( P > 0·9), demonstrating that t(6;9) is a high‐risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of FLT3 ‐ITD.